Literature DB >> 2167283

Histologic sampling requirements in ovarian carcinoma: a review of 51 tumors.

T Gramlich1, R M Austin, M Lutz.   

Abstract

In a review of 29 serous and 22 mucinous adenocarcinomas of the ovary, we quantitated the various histologic patterns seen in these neoplasms in order to document histologic variability and assess current anecdotal recommendations (one section per 1-2 cm of maximum tumor diameter) for adequate histologic sampling of epithelial ovarian neoplasms. Mucinous carcinomas showed more histologic variation than serous carcinomas, but both showed substantial portions with benign or borderline histology in many neoplasms. One serous and one mucinous carcinoma were likely to have been classified as borderline tumors if only current sampling recommendations had been followed. The remaining adenocarcinomas were adequately sampled by current standard practice. The two tumors in question had unusual clinical and histological features which prompted additional sampling. Caution is particularly warranted when initial frozen section sampling shows features of borderline tumor histology or low grade epithelial atypia, especially in mucinous epithelial neoplasms where histologic variability is greatest.

Entities:  

Mesh:

Year:  1990        PMID: 2167283     DOI: 10.1016/0090-8258(90)90050-u

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

Review 1.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

2.  Increase of fallopian tube and decrease of ovarian carcinoma: fact or fake?

Authors:  Anne Kathrin Höhn; Sabine Klagges; Albrecht Gläser; Sabine Taubenheim; Nadja Dornhöfer; Jens Einenkel; Grit Gesine Ruth Hiller; Christine E Brambs; Lars-Christian Horn
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-11       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.